Results 131 to 140 of about 3,776 (143)
Talimogene Laherparepvec (T-VEC)
, 2021 Talimogene laherparepvec (T-VEC, IMLYGIC®) is the first approved oncolytic virotherapy for the treatment of patients with advanced melanoma. As the drug is administered intratumorally, it is mainly suitable for the treatment of (sub)cutaneous lesions ...
Dirk Grünhagen +2 more
exaly +2 more sources
Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma
Annals of Pharmacotherapy, 2017 Objective: To review the efficacy and safety of talimogene laherparepvec (T-VEC) as well as its pharmacology, pharmacokinetics, drug-drug interactions, handling procedures, cost considerations, and place in therapy.
Caroline Beaulieu +3 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Cancers, 2021Pier Francesco Ferrucci +2 more
exaly
An evaluation of talimogene laherparepvec for the treatment of melanoma
Expert Opinion on Biological Therapy, 2020exaly
Retreatment with Talimogene Laherparepvec for Advanced Melanoma
Immunotherapy, 2020Georgia Beasley +2 more
exaly
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma
BioDrugs, 2016Karly P Garnock-Jones
exaly
Talimogene Laherparepvec: Overview, Combination Therapy and Current Practices
Melanoma Management, 2016Cristina O’Donoghue
exaly
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma
Expert Opinion on Drug Metabolism and Toxicology, 2018exaly